Novartis gives up on FDA clearance for its biosimilar: 5 notes

(By Alia Paavola for Becker’s Hospital Review)

Novartis will stop working toward FDA approval for its biosimilar of rituximab, a medication used to treat certain cancers and rheumatoid arthritis, according to Reuters.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.